D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Economics and Finance D-index 30 Citations 4,100 110 World Ranking 2028 National Ranking 239

Overview

What is he best known for?

The fields of study he is best known for:

  • Health care
  • Law
  • Internal medicine

His primary areas of study are Public economics, Economic growth, Competition, Health policy and Health technology. His biological study spans a wide range of topics, including Conceptual framework, Transparency, Politics and Economic evaluation. His Economic growth research is multidisciplinary, incorporating elements of Economic impact analysis, Medical prescription, Corporate governance and Agricultural economics.

His Competition research includes elements of Generic drug, Convergence, Reference pricing, Marketing and Industrial organization. The concepts of his Health policy study are interwoven with issues in Legislation, Pharmacy, Actuarial science, Diagnosis management and End stage renal disease. He works mostly in the field of Health technology, limiting it down to topics relating to Process and, in certain cases, Flexibility and Value theory.

His most cited work include:

  • The rising burden of cancer in the developing world (313 citations)
  • Assessing the economic challenges posed by orphan drugs. (197 citations)
  • Encouraging the use of generic medicines: implications for transition economies. (150 citations)

What are the main themes of his work throughout his whole career to date?

Panos Kanavos mainly investigates Public economics, Health care, Health technology, Economic growth and Health economics. He has researched Public economics in several fields, including Reimbursement, Systematic review, Pharmaceutical policy, Health policy and Incentive. As a part of the same scientific family, he mostly works in the field of Reimbursement, focusing on Actuarial science and, on occasion, Orphan drug.

The various areas that Panos Kanavos examines in his Health technology study include Multiple-criteria decision analysis and Process. Health economics is a subfield of Public health that Panos Kanavos investigates. His research integrates issues of Family medicine, Sick leave, Gerontology and Economic cost in his study of Public health.

He most often published in these fields:

  • Public economics (16.17%)
  • Health care (15.04%)
  • Health technology (12.78%)

What were the highlights of his more recent work (between 2016-2021)?

  • Health technology (12.78%)
  • Public economics (16.17%)
  • Pharmaceutical policy (7.52%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Health technology, Public economics, Pharmaceutical policy, Multiple-criteria decision analysis and Health care. He has included themes like Process and Economic evaluation in his Health technology study. His Public economics research is multidisciplinary, incorporating perspectives in Reimbursement, Data collection, Generic drug, Systematic review and Cost containment.

The concepts of his Pharmaceutical policy study are interwoven with issues in Competition, Best practice, International trade, Price index and China. Panos Kanavos works in the field of Health care, namely Health policy. His Health policy study is concerned with Economic growth in general.

Between 2016 and 2021, his most popular works were:

  • Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (75 citations)
  • Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (66 citations)
  • The implementation of managed entry agreements in Central and Eastern Europe : findings and implications (54 citations)

In his most recent research, the most cited papers focused on:

  • Health care
  • Law
  • Internal medicine

The scientist’s investigation covers issues in Health technology, Context, Pharmaceutical policy, Public economics and Risk analysis. His Health technology study integrates concerns from other disciplines, such as Operations management, Health economics, Multiple-criteria decision analysis, Economic evaluation and Social value orientations. His Pharmaceutical policy study combines topics in areas such as Finance, Reimbursement and Price index.

His Public economics research incorporates themes from Health care and Generic drug. Panos Kanavos interconnects Cost–benefit analysis, Orphan diseases and Transparency in the investigation of issues within Risk analysis. His specific area of interest is Economic growth, where Panos Kanavos studies Health policy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

The rising burden of cancer in the developing world

Panos Kanavos.
Annals of Oncology (2006)

577 Citations

Assessing the economic challenges posed by orphan drugs.

Michael F. Drummond;David A. Wilson;Panos Kanavos;Peter Ubel.
International Journal of Technology Assessment in Health Care (2007)

318 Citations

Encouraging the use of generic medicines: implications for transition economies.

Derek R King;Panos Kanavos.
Croatian Medical Journal (2002)

256 Citations

Ensuring value for money in health care: the role of health technology assessment in the European Union

Corinna Sorenson;Michael Drummond;Panos Kanavos.
(2008)

236 Citations

Diabetes expenditure, burden of disease and management in 5 EU countries

Panos Kanavos;Stacey van den Aardweg;Willemien Schurer.
(2012)

213 Citations

Competition in off‐Patent Drug Markets: Issues, Regulation and Evidence

Panos Kanavos;Joan Costa-Font;Elizabeth Seeley.
Economic Policy (2008)

178 Citations

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

Aris Angelis;David Tordrup;Panos Kanavos.
Health Policy (2015)

177 Citations

Early chronic kidney disease: diagnosis, management and models of care

Olivier J. Wouters;Donal J. O'Donoghue;James Ritchie;Panos G. Kanavos.
Nature Reviews Nephrology (2015)

175 Citations

Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom

Steven G. Morgan;Meghan McMahon;Craig Mitton;Elizabeth Roughead.
Health Affairs (2006)

162 Citations

Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.

Alessandra Ferrario;Panos Kanavos.
Social Science & Medicine (2015)

136 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Panos Kanavos

Michael Drummond

Michael Drummond

University of York

Publications: 22

Maarten J. Postma

Maarten J. Postma

University of Groningen

Publications: 20

Hubert G. M. Leufkens

Hubert G. M. Leufkens

Utrecht University

Publications: 19

Odd Rune Straume

Odd Rune Straume

University of Bergen

Publications: 14

Stephen Campbell

Stephen Campbell

University of Manchester

Publications: 13

Martin McKee

Martin McKee

University of London

Publications: 13

Martin Knapp

Martin Knapp

London School of Economics and Political Science

Publications: 10

Dennis Ross-Degnan

Dennis Ross-Degnan

Harvard University

Publications: 9

Hanns Lochmüller

Hanns Lochmüller

Children's Hospital of Eastern Ontario

Publications: 8

Joan Costa-Font

Joan Costa-Font

London School of Economics and Political Science

Publications: 7

Corrado Barbui

Corrado Barbui

University of Verona

Publications: 7

Lawrence N. Shulman

Lawrence N. Shulman

University of Pennsylvania

Publications: 6

Richard Harding

Richard Harding

King's College London

Publications: 6

Patricia M. Danzon

Patricia M. Danzon

University of Pennsylvania

Publications: 6

Something went wrong. Please try again later.